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Gestation-specific reference intervals for
comprehensive spot urinary steroid hormone
metabolite analysis in normal singleton
pregnancy and 6 weeks postpartum
Hiten D. Mistry1, Nicole Eisele1, Geneviève Escher1, Bernhard Dick1, Daniel Surbek2, Christian Delles3,
Gemma Currie3, Dietmar Schlembach4, Markus G. Mohaupt1,5*† and Carine Gennari-Moser1†
Abstract
Background: Normal pregnancy depends on pronounced adaptations in steroid hormone concentrations.
Although in recent years, the understanding of these hormones in pregnancy has improved, the interpretation is
hampered by insufficient reference values. Our aim was to establish gestation-specific reference intervals for spot
urinary steroid hormone levels in normal singleton pregnancies and 6 weeks postpartum.
Methods: Cross-sectional multicentre observational study. Women recruited between 2008 and 2013 at 3 University
Hospitals in Switzerland (Bern), Scotland (Glasgow) and Austria (Graz). Spot urine was collected from healthy
women undergoing a normal pregnancy (age, 16–45 years; mean, 31 years) attending routine antenatal clinics at
gestation weeks 11, 20, and 28 and approximately 6 weeks postpartum. Urine steroid hormone levels were analysed
using gas-chromatography mass spectrometry. Creatinine was also measured by routine analysis and used for
normalisation.
Results: From the results, a reference interval was calculated for each hormone metabolite at each trimester and
6 weeks postpartum. Changes in these concentrations between trimesters and postpartum were also observed for
several steroid hormones and followed changes proposed for index steroid hormones.
Conclusions: Normal gestation-specific reference values for spot urinary steroid hormones throughout pregnancy
and early postpartum are now available to facilitate clinical management and research approaches to steroid
hormone metabolism in pregnancy and the early postpartum period.
Keywords: Pregnancy reference values, Urine, Steroid metabolites
Background
A successful healthy pregnancy is recognised by
pregnancy-related changes in hormone concentrations,
characterised by elevated levels of several circulating
steroid hormones, which normally increase as preg-
nancy progresses [1, 2]. Changes in maternal hormone
concentrations play a critical role in modulating the
metabolic and immunological changes required for suc-
cessful pregnancy outcome; they also have an important
counterpart as the fetoplacental unit develops. There is
interest in how endogenous steroid hormones and their
respective metabolites have influence or are altered in
studies during pregnancy with respect to fetal size, pre-
term birth, multiple pregnancies, regulation of parti-
tion, hypertensive disorders of pregnancy and other
conditions [3–5]. Many of these previously published
studies on steroid metabolite concentrations have pro-
duced inconsistent findings, mainly due to technological
issues or lack of specificity. However, the development of
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sensitive mass spectrometry based assays that can accur-
ately measure individual steroid hormone concentrations
[6], allows improvement of our understanding of
gestation-dependent trends of these hormones. As many
conventional assays such as radioimmuno assays (RIA)
or enzyme-linked immunosorbent assays (ELISA) are
compromised by significant cross-reactivity and lack of
specificity, future analyses will require mass spectrometry
or other more specific techniques [7]. Earlier studies
using GC-MS-based techniques in pregnancy reported
analyses in different biological fluids, such as in plasma
samples [8], in low numbers of pregnant women [9], in
disease states [10, 11] and providing only partial steroid
hormone panels [9].
Physiological changes in pregnancy, including 50 %
plasma volume expansion or significant changes in bind-
ing protein concentrations, mean that plasma levels and
non-pregnant urinary steroid hormone reference intervals
may not be appropriate in pregnancy [12]. Although in
recent years, our understanding of the role of these hor-
mones in pregnancy has improved, the interpretation of
these levels is still difficult. We are not aware of any previ-
ous work reporting spot urinary steroid metabolite profiles
during pregnancy, calculating reference intervals recom-
mended for cross-sectional data that varies with gesta-
tional age [13, 14].
Given the importance of changes in steroid hormones
during pregnancy and that reliable, clinically and scientif-
ically useful reference intervals are not available for urine;
we set out to determine gestation-specific reference inter-
vals in a cross-sectional study of women during normal
pregnancy and 6 weeks postpartum. Furthermore, due to
the problems associated with collection of 24 h urine,
especially during pregnancy, an advantage of this study
was to produce reference values using spot urines from 3
different populations.
Materials and methods
Subjects
A first set of cross-sectional healthy pregnant women re-
cruited to the Bernese pregnancy registry were included
in the study. Visits were at week 11 ± 2 (n = 25), 20 ± 2
(n = 32), 28 ± 2 (n = 26) and approximately 6 weeks post-
partum (n = 40). The study was approved by the ethics
committee of the Canton of Berne, Switzerland.
A second set of samples were derived from a large
prospective pregnancy cohort from the Queen Mother’s,
Princess Royal Maternity and Southern General Hospi-
tals in Glasgow, Scotland. First trimester samples (11 ±
2 weeks’ gestation; n = 46) were taken at booking. The
study was approved by the ethics committee of the West
of Scotland Research Ethics Committee.
The third cohort of samples consisted of women from
Graz, Austria. Cross-sectional samples were obtained
from each trimester (weeks 11 ± 2 (n = 10), 20 ± 2 (n = 8)
and 28 ± 2 (n = 14)) following ethical approval from the
University of Graz, Austria.
All study subjects included from the 3 cohorts were in
keeping with the declaration of Helsinki and all partici-
pants provided written, informed consent. Only those
women maintaining a regular, normotensive, uncompli-
cated pregnancy without gestational diabetes, hepatic,
renal or other obvious diseases with no fetal abnormalities
such as fetal growth restriction were included in this
study. Clinical data were prospectively collected and either
existing hospital files or the woman’s personal history
reviewed to exclude any pre-existing disease, including
pregnancy outcome. In total, 81 samples were used from
the first trimester and 40 for all other trimesters and
postpartum.
Urine sampling
Morning fasting urine samples were obtained from preg-
nant women as has been described for population-based
assessments [15]. In all urine collections, sodium and
creatinine concentrations were determined using routine
methods. Urine aliquots were stored at −80 °C until fur-
ther analysis.
Assessment of urinary steroid hormones by GC-MS
Steroid hormone measurements for samples from all 3
cohorts were conducted in Bern using the same GC-MS
method, as described earlier [6, 7, 16]. In short, prepar-
ation consisted of pre-extraction, enzymatic hydrolysis,
extraction from the hydrolysis mixture, derivatisation and
gel filtration. All solvents were purchased from Merck,
USA). Medroxyprogesterone (2.5 μg; Steraloids, Inc.
Switzerland) was added as recovery standard to 1.5 ml
urine. The sample was extracted on a Sep Pak C18
column (Waters, Switzerland), dried, reconstituted in
0.1 M acetate buffer (pH 4.6) and hydrolyzed with pow-
dered Helix pomatia enzyme (12.5 mg, Sigma-Aldrich,
UK) and 12.5 μl of β-glucuronidase/arylsulfatase liquid
enzyme (Roche, USA) at 55 °C for 3 h. The resulting free
steroids were extracted on a Sep Pak C18 cartridge and
2.5 μg stigmasterol (Steraloids, Inc. Switzerland) plus
0.15 μg of 3β5β-TH-Aldo (custom-made by Taros Chemi-
cals, Germany) were added as a standard for derivatisation
Table 1 Basic demographic and pregnancy data from there
cohorts used in the study
Parameter Bern Glasgow Graz
Maternal Age (yrs) 31.5 ± 3.8 29.6 ± 6.3 31.8 ± 5.3
Booking BMI (kg/m2) 25.5 ± 3.8 24.3 ± 5.4 23.8 ± 3.7
Gestational age at delivery (Wks) 39 ± 1.2 40 ± 1.2 39 ± 1.3
Birthweight (g) 3505 ± 658 3477 ± 530 3304 ± 346
Baby gender (% male) 51 46 40
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Table 2 Steroid hormone metabolite[μg/mmol urinary creatinine]
1st trimester (n = 81) 2nd trimester (n = 40) 3rd trimester (n = 40)
Reference intervals Reference intervals Reference intervals
move to a separate row Mean ±
SD
Median 2.5th percentile
[90 % CI]
97.5th percentile
[90 % CI]
Mean ±
SD
Median 2.5th percentile
[90 % CI]
97.5th percentile
[90 % CI]
Mean ±
SD
Median 2.5th percentile
[90 % CI]
97.5th percentile
[90 % CI]
Androsterone 322 ± 196 289 40.0 [36.0, 91.7] 764 [740, 780] 209 ± 172 159 17.3 [16.6, 55.5] 746 [665, 748] 237 ± 274 134 5.9 [5.5, 38.0] 1409 [844, 1423]
Etiocholanolone 231 ± 141 211 31.0 [30.9, 65.3] 617 [542, 688] 149 ± 95.4 126 24.0 [23.7, 61.5] 518 [355, 522] 163 ± 176 108 6.5 [6.0, 34.9] 774 [707, 776]
11-Oxo-Etiocholanolon 38.6 ± 18.7 37.6 6.3 [1.7, 11.5] 84.4 [74.1, 87.0] 38.0 ± 19.0 35.1 6.4 [6.3, 15.3] 77.8 [72.7, 77.9] 49.1 ± 52.3 36.7 5.8 [5.8, 13.5] 325 [125, 325]
11β-Hydroxy-Androsterone 89.8 ± 53.3 75.1 20.8 [17.1, 23.1] 233 [212, 234] 70.8 ± 44.3 62.6 7.3 [7.1, 21.2] 192 [188, 193] 94.3 ± 123 58.7 4.9 [4.5, 21.4] 716 [315, 726]
11β-Hydroxy-
Etiocholanolon
31.5 ± 22.1 29.3 5.7 [4.8, 8.6] 83.8 [65.3, 163] 39.5 ± 28.6 28.6 3.2 [3.1, 11.6] 112 [97.7, 112] 43.4 ± 28.8 37.0 10.6 [10.5, 12.7] 141 [105, 141]
Dehydroepiandrosterone 86.2 ± 158 23.1 1.5 [1.5, 4.4] 759 [569, 774] 49.6 ± 87.5 18.4 0.7 [0.7, 2.1] 380 [348, 380] 61.6 ± 167 12.0 1.3 [1.3, 2.5] 919 [520, 929]
5-Androstene-3β,17β-diol 26.8 ± 25.6 18.8 1.4 [0.9, 4.1] 125 [78.0, 144] 20.1 ± 16.1 16.0 0.9 [0.9, 5.1] 85.3 [55.2, 86] 25.5 ± 29.8 17.9 1.0 [1.0, 5.5] 175 [69.0, 175]
5-Androstene-3β,17β-triol 17.3 ± 57.2 5.3 0.7 [0.7, 1.8] 225 [92.6, 454] 10.9 ± 33.0 2.6 0.8 [0.8, 1.0] 164 [139, 165] 9.9 ± 20.8 2.6 0.7 [0.7, 0.9] 115 [51.5, 115]
16α-Hydroxy-
dehydroepiandrostrerone
96.4 ± 101 60.7 2.9 [1.2, 14.4] 415 [277, 600] 107 ± 107 88.7 2.1 [2.0, 12.5] 569 [259, 577] 154 ± 340 77.5 3.4 [3.3, 13.0] 2139 [376, 2139]
5-Androstene-3β,16α,17β-
triol
84.3 ± 75.0 55.8 9.2 [7.5, 22.2] 278 [209, 306] 65.4 ± 60.0 52.8 11.7 [11.7, 27.7] 313 [127, 317] 107 ± 155 60.2 12.4 [12.3, 18.5] 868 [454, 868]
5-Pregnene-3β,16α,17,20α-
triol
48.2 ± 56.5 36.8 1.2 [0.9, 3.5] 317 [161, 397] 20.6 ± 25.5 13.6 0.9 [0.9, 2.1] 151 [50.7, 154] 38.1 ± 111 11.4 1.7 [1.7, 2.9] 690 [107, 690]
Testosterone 2.0 ± 1.8 1.6 0.3 [0.2, 0.5] 9.4 [6, 11.1] 2.4 ± 3.2 1.3 0.3 [0.3, 0.4] 18.5 [7.4, 18.8] 3.6 ± 5.6 2.0 0.5 [0.5, 0.7] 27.8 [27.8, 28.1]
5α-Dihydrotestosterone 4.6 ± 3.2 3.6 0.6 [0.5, 1.1] 12.3 [11.4, 12.9] 3.7 ± 2.6 3.2 0.5 [0.5, 1.2] 11.1 [10.1, 11.1] 5.7 ± 3.7 4.6 0.4 [0.4, 1.7] 19.1 [11.3, 19.3]
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Table 3 Steroid hormone metabolite[μg/mmol urinary creatinine]
1st trimester (n = 81) 2nd trimester (n = 40) 3rd trimester (n = 40)
Reference intervals Reference intervals Reference intervals
move to a separate row Mean ± SD Median 2.5th
percentile
[90 % CI]
97.5th
percentile
[90 % CI]
Mean ± SD Median 2.5th percentile
[90 % CI]
97.5th
percentile
[90 % CI]
Mean ± SD Median 2.5th
percentile
[90 % CI]
97.5th
percentile
[90 % CI]
Estriol 135 ± 151 79.9 10.6 [3.5, 17.0] 545 [489, 901] 975 ± 584 836 143 [143, 2881] 2877 [2660, 2881] 2651 ± 2651 1955 636 [636, 764] 15192
[9171, 15116]
17β-Estradiol 9.1 ± 6.7 7.3 0.7 [0.6, 2.1] 26.4 [24.8, 28.8] 16.6 ± 12.0 14.5 1.8 [1.8, 4.6] 63.5 [45.0, 64.0] 25.2 ± 25.2 24.0 2.3 [2.3, 8.9] 117
[111, 117]
Progesterone metabolites
Pregnenolone 14.2 ± 10.0 12.5 2.8 [2.6, 4.2] 53.0 [41.3, 54] 18.0 ± 14.7 14.9 1.9 [1.9, 3.3] 65.3 [57.3, 65.5] 27.9 ± 42.4 16.9 4.2 [4.2, 6.2] 265
[94.2, 265]
17-Hydroxypregnanolone 91.0 ± 76.4 79.5 14.6 [9.1, 23.1] 229 [202, 599] 88.3 ± 55.5 72.8 18.8 [18.7, 41.9] 247 [238, 247] 189 ± 253 113 34.1 [34.2, 50.6] 1298
1051, 1298]
Pregnanediol 1269 ± 830 1110 215 [154, 416] 4257 [3093, 4405] 1765 ± 1291 1461 459 [457, 633] 7514 [4181, 7602] 3982 ± 3762 2877 785 [779, 1162] 21112
[11216, 21112]
Pregnanetriol 209 ± 114 191 53.9 [34.2, 80.9] 455 [378, 774] 182 ± 94.0 153 35.8 [34.6, 99.6] 480 [443, 481] 287 ± 321 191 53.9 [53.4, 89.2] 1865
[970, 1865]
11-Oxopregnanetriol 2.7 ± 2.7 2.0 0.4 [0.3, 0.7] 11.8 [10.5, 14.7] 2.8 ± 4.4 1.5 0.3 [0.3, 0.7] 26.4 [10.0, 26.9] 11.3 ± 29.2 1.9 0.2 [0.2, 0.5] 151
[99.2, 1501]
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Table 4 Steroid hormone metabolite[μg/mmol urinary creatinine]
1st trimester (n = 81) 2nd trimester (n = 40) 3rd trimester (n = 40)
Reference intervals Reference intervals Reference intervals
move to a separate row Mean ±
SD
Median 2.5th percentile
[90 % CI]
97.5th percentile
[90 % CI]
Mean ±
SD
Median 2.5th percentile
[90 % CI]
97.5th percentile
[90 % CI]
Mean ± SD Median 2.5th percentile
[90 % CI]
97.5th percentile
[90 % CI]
Tetrahydro-11-
deoxycortisol
17.1 ± 10.1 15.5 2.7 [1.2, 6.9] 43.1 [35.1, 62.5] 23.2 ± 11.5 21.2 5.2 [5.1, 11.3] 56.2 [51.9, 56.3] 37.1 ± 27.4 31.6 8.9 [8.9, 11.4] 146 [110, 147]
Tetrahydro-11-
deoxycorticosterone
12.5 ± 8.8 10.2 1.7 [0.9, 3.8] 40.1 [33.9, 46.6] 35.3 ± 102 16.1 4.1 [4.1, 5.9] 643 [466, 629] 588 ± 1681 31.6 6.1 [6.1, 14.7] 8789 [5075, 8875]
Corticosterone metabolites
Tetrahydroaldosterone 15.4 ± 10.7 12.0 2.7 [2.1, 5.0] 49.8 [36.5, 65.6] 18.2 ± 19.5 11.4 1.6 [1.6, 3.9] 114 [40.6, 116] 22.9 ± 16.6 18.2 2.1 [2.1, 7.1] 87.1 [55.1, 87.9]
Tetrahydro-11-
dehydrocorticosterone
33.6 ± 23.7 26.7 3.9 [3.2, 10.9] 108 [88.5, 130] 35.1 ± 19.3 30.3 10.2 [10.1, 15.8] 89.4 [87.1, 89.4] 88.0 ± 88.9 56.1 13.4 [13.3, 27.4] 385 [371, 386]
Tetrahydrocorticosterone
23.1 ± 12.7 21.4 3.4 [3.0, 8.1] 57.8 [48.5, 63.4] 25.8 ± 13.2 22.3 3.3 [3.2, 8.5] 57.9 [55.0, 58.0] 83.0 ± 107.3 43.4 15.2 [15.1, 22.5] 586 [344, 591]
5α-Tetrahydro-
corticosterone
51.5 ± 39.3 39.8 5.9 [4.3, 13.9] 189 [143, 194] 33.8 ± 21.6 30.0 1.7 [1.6, 9.8] 93.0 [91.7, 93] 59.0 ± 62.4 33.8 5.6 [5.6, 15.0] 304 [241, 306]
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Table 5 Steroid hormone metabolite[μg/mmol urinary creatinine]
1st trimester (n = 81) 2nd trimester (n = 40) 3rd trimester (n = 40)
Reference intervals Reference intervals Reference intervals
move to a separate row Mean ±
SD
Median 2.5th percentile
[90 % CI]
97.5th percentile
[90 % CI]
Mean ±
SD
Median 2.5th percentile
[90 % CI]
97.5th percentile
[90 % CI]
Mean ±
SD
Median 2.5th percentile
[90 % CI]
97.5th percentile
[90 % CI]
Cortisone 34.6 ± 25.2 28.4 4.7 [4.4, 10.2] 110 [97.7, 113] 64.5 ± 39.8 53.3 14.1 [14.0, 25.8] 165 [161, 165] 79.1 ± 43.0 82.3 4.8 [4.7, 22.6] 180 [144, 181]
Tetrahydrocortisone 368 ± 165 349 77.6 [73.4, 162] 780 [644, 624] 308 ± 190 255 73.8 [73.4, 90.5] 948 [926, 947] 321 ± 210 267 5.9 [4.7, 101] 923 [748, 922]
α-Cortolon 227 ± 170 211 27.6 [17.7, 35.8] 715 [641, 725] 112 ± 138 75.9 15.7 [15.7, 26.0] 826 [583, 825] 148 ± 196 68.7 17.5 [17.5, 22.5] 752 [741, 752]
β-Cortolon 47.9 ± 37.9 43.4 2.5 [1.5, 5.1] 141 [122, 167] 27.5 ± 36.5 13.3 3.8 [3.8, 4.8] 179 [148, 178] 35.0 ± 55.1 11.2 3.6 [3.5, 7.5] 303 [122, 308]
Cortisone 34.6 ± 25.2 28.4 4.7 [4.4, 10.2] 110 [97.7, 113] 64.5 ± 39.8 53.3 14.1 [14.0, 25.8] 165 [161, 165] 79.1 ± 43.0 82.3 4.8 [4.7, 22.6] 180 [144, 181]
20α-Dihydrocortisone 5.4 ± 3.2 4.3 1.5 [1.4, 2.2] 14.9 [12.9, 15.2] 8.2 ± 3.8 7.2 2.4 [2.4, 4.2] 15.0 [14.3, 15.0] 9.8 ± 4.7 9.4 1.4 [1.4, 4.3] 19.1 [18.9, 19.1]
20β-Dihydrocortisone 22.2 ± 11.9 21.2 4.2 [3.7, 8.2] 52.7 [49.9, 54.2] 34.0 ± 16.5 35.3 5.7 [5.6, 12.6] 70.0 [67.4, 70.0] 45.8 ± 26.9 37.7 1.8 [1.7, 14.2] 109 [104, 109]
Cortisol metabolites
Cortisol 29.1 ± 23.4 20 4.7 [1.5, 7.6] 102 [83.7, 119] 52.3 ± 42.3 38.8 7.9 [7.8, 17.3] 210 [168, 210] 98.2 ± 109 69.6 2.7 [2.5, 24.5] 641 [285, 650]
Tetrahydrocortisol 191 ± 99.6 178 26.2 [22.2, 73.1] 405 [389, 519] 136 ± 68.1 131 31.4 [31.2, 58.8] 296 [277, 296] 182 ± 202 123 15.7 [15.6, 52.9] 923 [823, 926]
5α-Tetrahydrocortisol 126 ± 111 90.0 13.2 [9.6, 27.8] 412 [379, 538] 54.7 ± 42.2 54.7 4.6 [4.6, 18.4] 158 [157, 158] 46.7 ± 55.2 29.2 1.3 [1.2, 10.3] 258 [218, 259]
α-Cortol 55.5 ± 32.0 49.9 8.9 [8.2, 18.5] 145 [111, 192] 37.4 ± 17.9 34.6 7.1 [6.9, 18.6] 107 [73.5, 108] 51.1 ± 56.5 35.1 6.0 [5.9, 12] 248 [235, 248]
β-Cortol 45.6 ± 22.8 39.9 14.9 [11.8, 21.0] 118 [10.0, 122] 32.4 ± 16.7 26.6 6.9 [6.7, 15.2] 80.0 [68.2, 80.3] 36.3 ± 33.5 24.1 6.3 [6.2, 13.2] 187 [101, 189]
20α-Dihydrocortisol 30.0 ± 33.7 19.7 1.9 [1.8, 6.6] 180 [117, 215] 60.4 ± 60.2 37.3 1.7 [1.6, 9.5] 258 [246, 258] 145 ± 203 74.8 5.1 [4.9, 18.3] 1049 [623, 1060]
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Table 6 Postpartum urinary steroid hormone concentrations
6 weeks postpartum (n = 40)
Steroid μg per mmol creatinine Reference intervals
move to a separate row Mean ± SD Median 2.5th percentile [90 % CI] 97.5th percentile [90 % CI]
Androsterone 130 ± 116 99.8 6.5 [6.2, 24.2] 524 [482, 525]
Etiocholanolone 180 ± 120 149 19.4 [19.3, 42.7] 456 [423, 457]
11-Oxo-Etiocholanolone 51.0 ± 35.1 42.1 8.0 [8.0, 14.9] 156 [149, 156]
11β-Hydroxy-Androsterone 77.5 ± 51.4 71.1 4.4 [4.2, 19.1] 262 [149, 156]
11β-Hydroxy-Etiocholanolone 46.4 ± 36.6 38.3 4.8 [4.8, 9.3] 161 [150, 161]
Dehydroepiandrosterone 33.5 ± 57.1 10.4 0.8 [0.8, 2.7] 291 [160, 294]
5-Androstene-3β,17β-diol 14.2 ± 15.1 9.4 0.4 [0.4, 1.6] 68.0 [50.0, 68.4]
5-Androstene-3β,17β-triol 9.8 ± 21.5 3.1 0.2 [0.2, 0.6] 113 [76.5, 114]
16α-Hydroxy-dehydroepiandrostrerone 46.8 ± 86.8 22.8 0.9 [0.9, 3.1] 502 [212, 510]
5-Androstene-3β,16α,17β-triol 40.4 ± 45.9 29.6 3.7 [3.6, 9.5] 271 [116, 275]
5-Pregnene-3β,16α,17,20α-triol 13.5 ± 12.5 10.7 0.4 [0.4, 1.3] 59.5 [38.9, 60.0]
Testosterone 3.7 ± 5.7 1.4 0.1 [0.1, 0.5] 26.0 [22.9, 26.1]
5α-Dihydrotestosterone 2.5 ± 2.3 2.2 0.1 [0.1, 0.6] 12.4 [8.2, 12.3]
Oestrogen metabolites
Estriol 119 ± 339 17.6 0.9 [0.9, 1.4] 2011 [557, 2049]
17β-Estradiol 2.9 ± 9.6 0.5 0.1 [0.05, 0.1] 58.7 [9.0, 60.0]
Progesterone precursor and metabolites
Pregnenolone 9.8 ± 13.4 4.7 0.2 [0.2, 0.7] 52.5 [49.7, 52.2]
17-Hydroxypregnanolone 20.2 ± 41.4 9.9 0.9 [0.9, 2.4] 257 [76.6, 262]
Pregnanediol 257 ± 668 76.2 10.4 [10.3, 29.5] 4052 [1173, 4126]
Pregnanetriol 56.0 ± 49.7 44.3 5.9 [5.7, 20.8] 297 [144, 301]
11-Oxo-Pregnanetriol 2.8 ± 3.4 1.6 0.4 [0.4, 0.7] 17.7 [10.1, 17.8]
11-Deoxysteroid metabolites
Tetrahydro-11-deoxycortisol 11.1 ± 8.6 9.8 0.7 [0.7, 3.0] 43.1 [30.6, 42.8]
Tetrahydro-11-deoxycorticosterone 28.2 ± 160 1.3 0.1 [0.1, 0.4] 989 [27.0, 1014]
Corticosterone metabolites
Tetrahydroaldosterone 4.2 ± 4.6 2.6 0.5 [0.5, 1.1] 21.9 [19.3, 21.9]
Tetrahydro-11-dehydrocorticosterone 20.7 ± 23.5 14.6 0.4 [0.4, 3.3] 139 [53.9, 142]
Tetrahydrocorticosterone 23.8 ± 16.7 20.1 2.2 [2.2, 6.8] 71.3 [69.3, 71.3]
5a-Tetrahydrocorticosterone 35.7 ± 28.1 28.8 1.7 [1.6, 6.3] 143 [113, 143]
Cortisone metabolite
Cortisone 28.2 ± 20.1 23.4 1.0 [1.0, 10.3] 101 [74.8, 101]
Tetrahydrocortisone 397 ± 233 373 58.8 [58.2, 120] 1034 [906, 1037]
α-Cortolon 122 ± 117 90.5 18.1 [18, 33.5] 707 [286, 718]
β-Cortolon 30.6 ± 40.4 6.1 0.2 [0.2, 1.5] 156 [141, 155]
20α-Dihydrocortisone 3.4 ± 2.7 2.7 0.2 [0.2, 1.1] 13.5 [9.7, 13.6]
20β-Dihydrocortisone 9.2 ± 6.9 8.1 0.5 [0.4. 3.1] 34.3 [24.5, 34.5]
Cortisol metabolites
Cortisol 20.8 ± 19.1 13.8 0.9 [0.8, 4.1] 99.7 [66.7, 99.7]
Tetrahydrocortisol 256 ± 153 243 30.7 [30.3, 80.3] 723 [599, 726]
5α-Tetrahydrocortisol 97.1 ± 81.2 78.3 5.8 [5.4, 22.7] 381 [302, 383]
α-Cortol 41.1 ± 32.6 35.5 3.9 [3.8, 17.7] 203 [98.2, 206]
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and chromatography. The percentage recovery following
extraction for all the assays was >90 %. The samples were
derivatised to form methyloxime-trimethylsilyl ethers. The
derivatives were purified by gel filtration on Lipidex 5000
(Perkin Elmer, USA) columns. Analysis was performed on
a Hewlett-Packard gas chromatograph 6890 (Hewlett-
Packard, Palo Alto, California, USA) with mass selective
detector 5973 by selective ion monitoring (SIM). A steroid
mixture containing a known amount of all steroid metab-
olites to be measured was analysed on a regular basis to
act as a calibration standard. To control extraction vari-
ability, a control sample was run on each extraction panel.
All steroid concentrations were normalised to urine cre-
atinine values.
Assessment of urinary creatinine concentrations
Urinary creatinine concentrations were measured either
in the clinical laboratory or by a validated Quanti-
ChromTM Creatinine Assay Kit (DICT-500; BioAssay
Systems, Switzerland), with intra-assay coefficient of varia-
tions for both assays <5 %. Both assays were based on the
same method and reference samples were analysed on
both platforms to ensure similar results; measurement
variability between the 2 techniques was less than 5 %.
Statistics
Descriptive statistics, including upper and lower bounds
of reference intervals were calculated for each metabolite
separately by trimester and postpartum using SPSS ver-
sion 22. Reference intervals are described as the 2.5 and
97.5th percentiles, centred around the median with their
corresponding 90 % confidence intervals [17]. Virtanen
et al., states that sample sixes above 30 had smaller
changes in SDs and CVs in reference intervals and thus
at least 40 samples for each time point were used [14].
Data was found to be non-parametric following the
Kolmogorov-Smirnov test for normality of data distribu-
tion, thus robust methods, with bootstrapping was used,
which utilises an interactive process to estimate location
and spread of the data [18].
Results
Participants
Basic demographic, obstetric and pregnancy description
data of the women in this study are detailed in Table 1.
Overall, the 3 cohorts were well matched with no
significant differences observed for all demographic data.
The majority of women who participated in this study
were White European (>95 %) from all 3 centres.
Reference intervals
All steroid hormone concentrations, normalised to cre-
atinine, grouped by trimester and steroid hormone are
given in Tables 2, 3, 4 and 5 and the postpartum values
are presented in Table 6, including the 2.5 and 97.5 %
reference intervals. For ease of clinical use, the mean
and median value for each steroid hormone metabolite
has also been calculated, normalised to creatinine con-
centrations (Tables 2, 3, 4, 5 and 6).
Androgen metabolites
For clarity, androgens are presented in 2 graphs as
follows: Fig. 1a: androsterone, etiocholanolone, 11-oxo-
etiocholanolone 11β-hydroxy-androsterone, dehydro-
epiandrosterone, 16α-hydroxydehydroepiandrosterone
and 5-androstene-3β,16α,17β-triol. Figure 1b: 11β-hy-
droxy-etiocholanolone, 5-androstene-3β,16α,17β-diol, 5-
androstene-3β,16α,17β-triol, 5-pregnene-3β,16α,17,20α-
triol, testosterone and 5α-dihydrotestosterone.
Oestrogen metabolites
Both estriol and 17β-estradiol differed between the tri-
mesters and postpartum (Fig. 2a); with the highest con-
centrations in the third trimester, followed by a dramatic
decrease postpartum, lower than first trimester concen-
trations (Fig. 1a).
Progesterone precursor and metabolites
The progesterone percursor, pregnenolone and all the
progesterone metabolites (17-hydroxypregnanolone,
pregnanetriol, pregnanediol, and 11-oxo-pregnanetriol)
are presented in Fig. 2b. All metabolites increased be-
tween the 2nd and 3rd trimester, then subsequently fell
postpartum.
11-deoxysteroid hormone metabolites
Both tetrahydro-11-deoxycortisol and tetrahydro-11-
deoxycorticosterone concentrations were increased with
gestational age and decreased postpartum (Fig. 3a).
Table 6 Postpartum urinary steroid hormone concentrations (Continued)
β-Cortol 55.3 ± 29.2 50.1 10.0 [9.9, 25.8] 130 [114, 130]
20α-Dihydrocortisol 17.3 ± 22.6 9.3 0.2 [0.2, 3] 127 [50.7, 127]
6β-Hydroxycortisol 149 ± 25.8 26.5 0.9 [0.9, 8.1] 149 [77.9, 149]
18-Hydroxycortisol 322 ± 55.1 41.7 1.5 [1.4, 4.9] 322 [130, 322]
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Corticosterone metabolites
All metabolites differed between trimesters (Fig. 3b). Tet-
rahydroaldosterone and tetrahydrocorticosterone already
increased throughout pregnancy and then subsequently
decreased 6-weeks postpartum (Fig. 3b).
Cortisol and cortisone metabolites
For clarity, cortisol and cortisone metabolites are presented
in 2 graphs as follows: Fig. 4a: cortisol, tetrahydrocortisol,
5α-tetrahydrocortisol, α-cortol, β-cortol, 20α-dihydrocortisol,
6β-hydroxycortisol and 18-hydroxycortisol. Figure 4b: corti-
sone, tetrahydrocortisone, α-cortolon, β-cortolon, 20α-
dihydrocortisone and 20β-dihydrocortisone. The most
dramatic change was the increase in 18-hydroxycortisol dur-
ing the 3 trimesters and postpartum.
For all steroid hormone metabolites measured, we
tested whether any fetal gender specific differences were
detectable. No significant differences (P < 0.05) were ob-
served for any steroid hormone metabolites.
Discussion
We have investigated the changes in spot urinary con-
centrations of the main steroid hormone metabolites
throughout normal pregnancy and 6 weeks postpartum
Fig. 2 Urinary concentrations of (a) oestrogen metabolites and (b) progesterone precursor (pregnenolone) and progesterone metabolites in first,
second, third trimester and six weeks postpartum. Each point is presented as mean corrected for creatinine concentrations (μg/mmol creatinine)
Fig. 1 a and b Urinary concentrations of androgen metabolites in first, second, third trimester and six weeks postpartum. Each point is presented
as mean corrected for creatinine concentrations (μg/mmol creatinine)
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using a validated GC-MS method. Furthermore, we
have used appropriate analysis techniques to calculate
clinically relevant gestation-specific reference intervals.
These data illustrate the profound changes in maternal
steroidogenesis during pregnancy and indicate normal
functional changes such as of the hypothalamic-pituitary-
gonadal axis during pregnancy. A relationship between
pregnancy outcome and steroid hormone availability such
as for aldosterone has been established in the past by our
group for aldosterone and cortisol [19, 20]. It have been
known for many years that during the first 9 weeks of
pregnancy, the corpus luteum and, the maternal ovary
and adrenal cortex contribute to circulating concentra-
tions of maternal hormones [21, 22]. After this time, the
placenta becomes the predominant source of many mater-
nal steroids [23].
These can then be used to improve management of ster-
oid hormone related diseases in pregnancy, as well as
encourage the appreciation of the changes that occur in
steroid hormones during pregnancy. It will also allow
clinicians to use gestation-specific reference ranges for
management. Several steroid hormone metabolites are
often combined to provide the clinician with a general
picture of the individual’s steroid hormone production.
This is useful as first point of investigation to obtain an
integrated picture of the patient, to aid the identification
of inherited metabolic disorders of steroid metabolism,
and to perform non-invasive diagnostics. If normal values
for pregnancy are established, even prenatal diagnosis of
fetal disease might be feasible. Given the altered steroid
hormone profile in pregnancy, these normal values might
also allow discrimination between acquired, such as
adrenal adenomas, and inborn errors of metabolism [7]
(detailed on Table 7). Furthermore, some metabolites are
still the subject of research investigations in the future.
This could contribute to our knowledge of developmental
Fig. 4 Urinary concentrations (a) cortisol metabolites and (b) cortisone metabolites in first, second, third trimester and six weeks postpartum.
Each point is presented as mean corrected for creatinine concentrations (μg/mmol creatinine)
Fig. 3 Urinary concentrations of (a) 11-Deoxy-steroid hormone metabolites and (b) corticosterone metabolites in first, second, third trimester and
six weeks postpartum. Each point is presented as mean corrected for creatinine concentrations (μg/mmol creatinine)
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Table 7 Assignment of steroid hormone metabolites to their main reference
Full trivial name Reference Analyzed enzyme system
Androgen metabolites
Androsterone Androstenedione, testosterone,
5α-dihydrotestosterone, dehydroepiandrosterone
CYP17A1, POR, SRD5A2, HSD17B3
Etiocholanolone Testosterone, dehydroepiandrosterone CYP17A1, POR, SRD5A2, HSD17B3
11β-Hydroxy-androsterone 11β-hydroxy-androstenedione, cortisol
Dehydroepiandrosterone Dehydroepiandrosterone HSD3B2
5-Androstene-3β,17β-diol Testosterone, dehydroepiandrosterone
5-Androstene-3β,17β-triol Testosterone, dehydroepiandrosterone
16α-Hydroxy-dehydroepiandrosterone Dehydroepiandrosterone
5-Androstene-3β,16α,17β-triol Testosterone, dehydroepiandrosterone
11β-Hydroxy-etiocholanolone Testosterone, dehydroepiandrosterone, cortisol
11-Oxo-etiocholanolone Testosterone, dehydroepiandrosterone, cortisol
Testosterone Testosterone
5α-Dihydrotestosterone Testosterone
Oestrogen metabolites
Estriol Estradiol
17β-Estradiol Estradiol
Progesterone metabolites
Pregnenolone Pregnenolone
17-Hydroxypregnanolone 17-Hydroxy-progesterone CYP17A1, POR
Pregnanediol Pregnenolone POR
Pregnanetriol 17-Hydroxy-progesterone CYP21A2, POR
11-Oxopregnanetriol 17-Hydroxy-progesterone CYP21A2
5-Pregnene-3β,16α,17,20α-triol 17-Hydroxy-pregnenolone HSD3B2
11-Deoxysteroid hormone metabolites
Tetrahydro-11-deoxycortisol 11-Deoxycortisol CYP11B1
Tetrahydro-11-deoxycorticosterone Corticosterone
Corticosterone metabolites
Tetrahydrocorticosterone 11-Deoxycorticosterone CYP17A1, POR, SRD5A2
5α-Tetrahydrocorticosterone 11-Deoxycorticosterone CYP17A1, POR, SRD5A2
Tetrahydro-11-dehydrocorticosterone Corticosterone CYP17A1, POR
Tetrahydroaldosterone Aldosterone
Cortisol metabolites
Cortisol Cortisol HSD11B2
Tetrahydrocortisol Cortisol CYP21A2, CYP11B1, CYP17A1, HSD3B2, POR,
HSD11B2, H6PDH, HSD17B3
5α-Tetrahydrocortisol Cortisol CYP21A2, CYP11B1, CYP17A1, HSD3B2, POR,
HSD11B2, H6PDH, HSD17B3, SRD5A2
α-Cortol Cortisol HSD11B2
β-Cortol Cortisol HSD11B2
20α-Dihydrocortisol Cortisol
6β-Hydroxycortisol Cortisol
18-Hydroxycortisol Cortisol
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changes in synthesis and metabolism of steroid hormones,
such as the early diagnosis of congenital adrenal hyperpla-
sia [24].
The placenta is a site for active steroidogenesis, which
depends on highly integrated and active interactions
with both mother and fetus. As is well established, pro-
gesterone levels are important for normal feto-placental
function, playing essential roles in controlling and main-
taining the course of normal pregnancy [25, 26]. The
rises in these metabolites during pregnancy and subse-
quent fall postpartum are thus the normal responses
previously described [5]. Equally many of the changes in
mineralocorticoids and in glucocorticoids also reflect the
normal physiological responses to pregnancy and in
preparation for parturition [27].
Androgens derived from the maternal adrenal tissue can
undergo aromatization to form oestrogens [28]. Although
clinical manifestations of androgen excess are uncommon
in pregnant women, any physical changes in these metab-
olites from the normal changes described should be of
concern. After the first 5 to 6 weeks of pregnancy, the
major source of estradiol is the placenta, where enzymes
convert maternal and fetal dehydroepiandrosterone to
estradiol, estrone and estriol [22]. Near term, 50 % of es-
tradiol synthesised in the placenta is derived from precur-
sors in the fetal circulation; the remainder coming from
the maternal circulations. This explains the increased
levels of this and 17β-estradiol in the third trimester. It is
well known that the expulsion of the placenta causes a
decline in steroid levels [23], reflected and confirmed in
the postpartum concentrations in the current study.
These normal values reflect known changes in index
steroid hormone levels throughout pregnancy (e.g. in-
creases in oestrogen metabolites in the third trimester;
Fig. 2a). However, numerous studies might have benefited
from the addition of MS-based to conventional RIA- or
ELISA-based methods to obtain more accurate levels, by
avoiding interference with steroid hormone binding, not
missing important metabolites or simply by circumventing
cross-reactivity. Furthermore, urinary measurements are
not just a momentary picture, but integrate hormone
production over a given time span. The high accuracy and
specificity will now allow comprehensive clinical and sci-
entific analysis in pregnant women, which has recently
been postulated in the endocrine community [29]. The
multi-centric setup avoids centre bias, although given the
uncomplicated pre-analytics in steroid hormone metab-
olite analytics; such an issue is quite unlikely. Further
advantages of urinary samples include less invasiveness,
which is a huge benefit in pediatric and pregnant popu-
lations. We also expect that fetal pathologies might be
identified by maternal urine sampling in pregnancy.
Moreover, blood sampling reflects just a single time
point whereas the urine sampling allows a cumulative
integrated view of the steroid hormone metabolome
over the sampling period. Upon calculation of specific
metabolite ratios, conditions of adrenal origin and
other disorders might be diagnosed without the need of
timed sample collection [7]. A limitation of all steroid
studies, including ours, is the high variation between
patients, possibly due to the use of spot, as opposed to
24 h urine collections, and the variable physical activity
of participating individuals. Conversely, this is also a
strength of the study and obtaining accurate 24 h urine
collections are problematic, particularly during preg-
nancy and thus spot urine offers a suitable and more
practical method for assessment of steroid metabolites. In
addition, a large degree of day-to-day variation within
individuals has to be considered [30–33]. This study was
conducted primarily in a population of white European
descent and while the absolute values might be limited in
their generality, the hormonal patterns reflecting the HPG
and HPA axes might show sufficient similarities even in
different genetic backgrounds [31, 33–35]. The addition of
samples from 3 different populations, account for varia-
tions in diet and salt intakes and thus provides more
accurate reference intervals. Future work will establish
possible changes in these steroid profiles in 24 h urine col-
lections and in pathological pregnancies.
Conclusions
In summary, we have established, as far as we are aware,
for the first time, gestation-specific GC-MS based reference
values for spot urinary endogenous hormone metabolites
Table 7 Assignment of steroid hormone metabolites to their main reference (Continued)
Cortisone metabolites
Cortisone Cortisol, cortisone HSD11B2
Tetrahydrocortisone Cortisol, cortisone CYP21A2, CYP11B1, CYP17A1, HSD3B2, POR,
HSD11B2, H6PDH, HSD17B3
α-Cortolone Cortisol, cortisone HSD11B2
β-Cortolone Cortisol, cortisone HSD11B2
20α-Dihydrocortisone Cortisol, cortisone
20β-Dihydrocortisone Cortisol, cortisone
Mistry et al. Reproductive Biology and Endocrinology  (2015) 13:101 Page 12 of 13
during pregnancy, which may also be of interest in studies
of maternal and fetal health and disease. We have created
an easy to use functionally grouped trimester-based table
(Tables 2, 3, 4, 5 and 6) for each hormone, which will be of
use to those managing and studying women with respect to
steroid hormone metabolites in pregnancy.
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